Asset

  • No.

    102

  • Asset Title

    Differentiated CD38-CD3 Bionic to Treat AML

  • Organization

    City of Hope

  • Product Type

    Antibody

  • Therapeutic Area

    Oncology

  • Development Stage

    Hit To Lead or Lead Optimization

  • Technical Summary

    • Inventors have developed bispecific molecules (“bionics”) directed against CD38 and CD3 to target CD38-overexpressing cancers such as AML.

     

    • The molecules show significant advantages over conventional daratumumab therapy including that 

    – they kill AML cells w/o affecting human peripheral blood viability 

    – they specifically kill CD38+ cancer cells 

    – They engage with CD4 positive cells, leading to high levels of IFN-g production 

    – Local IFN-g induced CD38 on leukemic stem cells and their subsequent destruction

    – They do not kill human NK or T cells in co-culture assays

    – They exhibit favorable therapeutic/manufacturing properties extensive biochemical, in vitro and in vivo data (multiple animal models) are available under confidentiality 

     

    • The bionic technology is a platform that can be expanded to other antigens/bispecifics.

  • Patent

    WO2022094147A1

  • Publication

  • Attachment

TOP